Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.
暂无分享,去创建一个
R. Hustinx | G. Jerusalem | P. Rigo | G. Fillet | T. Belhocine | Y Beguin | P Rigo | Y. Beguin | G Jerusalem | M F Fassotte | G Fillet | R Hustinx | T Belhocine | M. Fassotte
[1] A. Belakhlef,et al. False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] U. Cremerius,et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. , 1998, Nuclear medicine communications.
[3] G. Jerusalem,et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. , 2001, Haematologica.
[4] P. Herman,et al. Comparison of CT and chest radiographs in the evaluation of post-therapy lymphoma patients. , 1989, European journal of radiology.
[5] S. Hain,et al. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] B Y Yeap,et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J Kotzerke,et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. , 1997, Radiology.
[8] M. Kaminski,et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. , 1994, Radiology.
[9] F. Gherlinzoni,et al. The role of positron emission tomography (PET) in the management of lymphoma patients. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] J. Radford,et al. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records , 1997, BMJ.
[11] P. Dupont,et al. Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? , 2001, British journal of haematology.
[12] M E Phelps,et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] H. Alibazoglu,et al. Normal thymic uptake of FDG on PET imaging. , 1996, Clinical nuclear medicine.
[14] G. Jerusalem,et al. Commentary on “Positron Emission Tomography in Lymphoma: Comparison with Computed Tomography and Gallium-67 Single Photon Emission Computed Tomography Imaging” , 2000 .
[15] C. Hill,et al. Thymic rebound after treatment of childhood tumors. , 1980, AJR. American journal of roentgenology.
[16] D Front,et al. Early detection of lymphoma recurrence with gallium-67 scintigraphy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] G. Jerusalem,et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. , 1999, Nuclear medicine communications.
[18] I. Magrath,et al. High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Hustinx,et al. Positron emission tomography ( PET ) with 18 F-fluorodeoxyglucose ( 18 F-FDG ) for the staging of low-grade non-Hodgkin ' s lymphoma ( NHL ) * , 2005 .
[20] V. Diehl,et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. , 2001, Blood.
[21] S. Hain,et al. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] R. Hustinx,et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose , 1996, European Journal of Nuclear Medicine.
[23] J. Poen,et al. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Hustinx,et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] M Schwaiger,et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.
[26] P. Dupont,et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] G. Jerusalem,et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. , 2000, Haematologica.
[28] F. Maul,et al. Whole body positron emission tomography in the treatment of Hodgkin disease , 2001, Cancer.
[29] R. Buchert,et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] M. Tubiana,et al. Evolution of erythrocyte sedimentation rate as predictor of early relapse in posttherapy early-stage Hodgkin's disease. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] G. Jerusalem,et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.
[32] G Hör,et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. , 1999, Leukemia & lymphoma.
[33] J Kotzerke,et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] M Tubiana,et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.